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Abstract

Hypoxia episodes and areas in tumours have been associated with metastatic dissemination and poor prognosis. Given the link between tumour tissue oxygen levels and cellular metabolic activity, we hypothesised that the metabolic profile between metastatic and non-metastatic tumours would reveal potential new biomarkers and signalling cues. We have used a previously established chick embryo model for neuroblastoma growth and metastasis, where the metastatic phenotype can be controlled by neuroblastoma cell hypoxic preconditioning (3 days at 1% O2). We measured, with fibre-optic oxygen sensors, the effects of the hypoxic preconditioning on the tumour oxygenation, within tumours formed by SK-N-AS cells on the chorioallantoic membrane of chick embryos. We found that the difference between the metastatic and non-metastatic intra-tumoural oxygen levels was small (0.35% O2), with a mean below 1.5% O2 for most tumours. The metabolomic profiling, using NMR spectroscopy, of neuroblastoma cells cultured in normoxia or hypoxia for 3 days and of the tumours formed by these cells showed that the effects of hypoxia in vitro did not compare to in vivo tumours. One notable difference was the high levels of the glycolytic end-products triggered by hypoxia in vitro, but not by hypoxia preconditioning in tumours, likely due to the very high basal levels of these metabolites in tumours compared to cells. In conclusion, we have identified high levels of ketones (3-hydroxybutyrate), lactate, and phospho-choline in hypoxic preconditioned tumours, all known to fuel tumour growth, and we herein point to the poor relevance of in vitro metabolomic experiments for cancer research. 
Introduction:

Neuroblastoma is the most common extracranial solid tumour in childhood and exhibits a broad spectrum of severity ranging from asymptomatic spontaneous regression to severe systemic illness, metastasis, and death. Metastatic tumour development and disease relapse are strongly associated with poor patient survival in neuroblastoma and critically need to be addressed in terms of improved detection and therapeutic intervention, through biological and clinical investigations  ADDIN EN.CITE [1, 2].
The occurrence of oxygen deprivation (hypoxia) in solid tumours is associated with cancer progression, treatment resistance and poor clinical outcome. Tumour hypoxia arises from a multifactorial aetiology ultimately resulting in O2 levels lower than the 2-9% physiological range found in most human tissue  ADDIN EN.CITE [3, 4]. While O2 levels <2% are regarded as hypoxic in many normal tissues, tumour environments are more oxygen deprived with O2 levels detected at less than 0.7% O2  ADDIN EN.CITE [5, 6]. The neuroblastoma hypoxic signature has previously been correlated to patient outcome [7] and we have further demonstrated, utilising the chick embryo chorioallantoic membrane (CAM) model, that hypoxic preconditioning drives metastasis and the regulation of genes supportive of tumour dissemination  ADDIN EN.CITE [8]. In addition, we observed that hypoxic preconditioned cells are able to trigger the invasion of adjacent non–metastatic cells  ADDIN EN.CITE [8]. Whilst tumour hypoxia has been extensively reported as a poor prognostic marker in disease, much remains to be discovered with regards to the intracellular modifications associated with hypoxia and their link with the metastatic phenotype  ADDIN EN.CITE [9, 10]. 
Various indirect and direct methods have been used to characterise tumour oxygen levels. Whilst indirect ex vivo methods often rely on injecting hypoxia markers and detecting them via flow cytometry or immunohistochemistry, direct in vivo methods have the advantage of providing spatial and temporal oxygen measurements. Such direct methods are more challenging and often require invasive devices such as oxygen sensitive microelectrodes or fibres-optic devices. Tumour oxygenation can also be assessed non-invasively using imaging techniques such as 19F magnetic resonance imaging (MRI), pulsed electron paramagnetic resonance imaging or positron emission tomography (PET) imaging with [F-18] fluoromisonidazole (FMISO)  ADDIN EN.CITE [5, 11, 12]. Such measurements showed that, in addition to chronic hypoxia, tumour cells experience acute, intermittent and cycling episodes of hypoxia, even in close proximity to arterial vasculature  ADDIN EN.CITE [11, 13]. There is emerging evidence that the different subtypes of hypoxia result in varied clinical outcomes, with acute or cycling hypoxia reported to be more aggressive when compared to chronic hypoxia [11]. Hence, the characterisation of neuroblastoma oxygenation is crucial for our understanding of its biological and clinical implications. However, despite advances in non–invasive techniques that monitor oxygen, clinical data on neuroblastoma are still missing. 
The cellular response to hypoxia involves alteration of gene expression via the stabilisation and activation of the Hypoxia Inducible Factor (HIF) [14]. This promotes cell survival by ensuring increased oxygen delivery and reduced oxygen consumption (increased glycolysis)  ADDIN EN.CITE [15-19]. Such metabolic change in tumours, classified as ‘deregulation of cellular energetics’, is an emerging hallmark of cancer [20]. Technological advances and low per-sample costs have contributed to the increase of metabolomic studies to elucidate the global metabolic changes occurring during cancer progression thereby defining novel oncological biomarkers [21]. Distinct metabolic profiles have already been described for certain tumours (e.g (​https:​/​​/​www.sciencedirect.com​/​science​/​article​/​pii​/​S1084952115001676" \l "bib0865​).  ADDIN EN.CITE [22]), and some metabolic biomarkers are already used in the clinic. Moreover, a number of drugs targeting metabolic pathways are employed as cancer treatments. However, routine elucidation of cancer metabolites as a general therapeutic/stratification strategy remains challenging and the identification of specific and defined metabolic markers using pre-clinical and clinical approaches is required. A recent meta-analysis of clinical metabolomic studies encompassing 18 types of cancer confirmed the consistency of increased glycolysis and highlighted metabolites previously less associated with cancer such as histidine, tryptophan, and 3-hydroxybutyric acid  ADDIN EN.CITE [23]. Although tumour tissue is more challenging to obtain and to prepare than common bio-fluid samples such as serum and urine, interest in direct tumour metabolomics has been increasing [24]. Specifically, the metabolome of neuroblastoma biopsy samples has recently been analysed to associate metabolites with patient age, prognosis, active disease, and remission [25].
We here aimed to elucidate, at a metabolic level, how hypoxic pre-conditioning alters the neuroblastoma cell metastatic phenotype, in order to identify potential new metabolic biomarkers of metastasis. We performed live oxygen measurements with a fibre-optic oxygen sensor to establish the oxygen levels in tumours formed by SK-N-AS neuroblastoma cells pre-conditioned in normoxia or hypoxia and implanted onto the chorioallantoic membrane of chick embryos. We demonstrated that neuroblastoma oxygen levels are heterogeneous and fluctuate spatially and temporally with the exception of necrotic or haemorrhagic areas. Hypoxic preconditioning resulted in a lower overall mean oxygen level in the tumour tissue, however more drastic changes were observed on the tumour metabolic profile, measured by 1D 1H Nuclear Magnetic Resonance (NMR) spectroscopy. Our analysis here demonstrates that the metabolic fingerprint of cell culture is only marginally comparable to the metabolic fingerprint of tumour tissues in vivo. Tumour samples have very high levels of choline/phosphocholine, taurine, glucose, fructose and lactate compared to cells, consistent with a higher level of glycolytic flux in vivo  ADDIN EN.CITE [26-31]. Hypoxic preconditioned tumours, which have a metastatic phenotype were associated with high levels of alanine, lactate, 3-hydroxybutyrate and decreased taurine levels, all in line with glycolysis and cancer progression [32]. 
Methods:
Cell Culture
SK-N-AS cells (ECACC No. 94092302; authenticated in April 2018; passage number typically between 13 and 33) were cultured in Minimum Essential Medium supplemented with 10% (v/v) foetal calf serum (FCS) and 1% (v/v) non-essential amino acids (all Thermo Fisher Scientific). Cells were maintained in a humidified incubator at 37°C, 5% CO2, and routinely tested for mycoplasma infection. For preconditioning, cells were incubated for 3 days in either 21% O2 (normoxia) or 1% O2 (hypoxia) in a hypoxic workstation (Don Whitley Hypoxic Workstation, England). We ensured that the cells grew at a similar rate in both oxygen conditions and that they also had a comparable viability (supplemental Figure S1A&B). GFP-labelled cells were used to implant onto the CAM for tumour development monitoring and precise tumour dissection. Non labelled cells were used for generating the in vitro samples. We established that the metabolic fingerprint of labelled and non-labelled cells was comparable (not shown).

CAM Implantation: 
Fluorescently labelled NB cells preconditioned in 1% or 21% O2 for 3 days were implanted on the CAM of chick embryos at embryonic day 7 (E7) as described previously [33]. At E14, intratumoural oxygen tension was measured as described below.

Oxygen Measurements:
Oxygen tension was monitored live in vivo in 80 tumour samples for a period up to 57 minutes and levels captured in 2 s intervals. 38 tumours originated from SK-N-AS cells pre-cultured in normoxia and 42 tumours from cells preconditioned in hypoxia. The measurements were carried out with a Microx 4 Fibre Optic Oxygen Meter fitted with a needle-type oxygen micro-sensor (Presens, Germany). Of the 80 tumours, 57 measurements were performed with the probe attached to a micromanipulator (Presens, Germany) to record fluctuation with maximal stability.

NMR samples:

Cell Harvesting:
1106 SK-N-AS cells were incubated in either 21% or 1% O2 for three days in T25 flasks (Corning, UK). Cells were harvested by a 2 ml PBS wash, trypsinisation and suspension in 5 ml media. A cell count was performed at harvesting time, and ~5-6106 cells were used for each condition. Supplementary Figure S1C shows a typical confluency at harvesting time for both normoxic and hypoxic conditions. In order to remove the residual culture media, cells were gently washed in PBS by repeated cycles of centrifugation and supernatant discard. Upon centrifugation (1200 g for 5 min), the supernatant was discarded and the pellet of cells was re-suspended in 1 ml PBS, centrifuged (1200 g for 5 min) and the pellet of cells was frozen immediately in liquid nitrogen and stored in -80 °C until acetonitrile:water extraction.

Tumour Harvesting:
On E14, the tumours were dissected from the CAM followed by a PBS wash, stored in an Eppendorf tube, and immediately frozen in liquid Nitrogen. Samples were stored in -80 °C until acetonitrile:water extraction.

Acetonitrile:water extraction:
An ice-cold solution of 50% high performance liquid chromatography-grade acetonitrile and 50% double distilled water was added to the samples without any further washing: 400 µl for cells and 1.2 ml to tumours. Tumours were subsequently divided into technical triplicates following sonication. Samples were sonicated (MSE UK Soniprep 150 Plus Ultrasonic Disintegrator) for 3 x 30 s cycles at 10 kHz using a microtip probe. The lysed samples were vortexed (30 s) followed by centrifugation (5 min. at 21,500 g / 4°C) to remove cell debris and the supernatants snap frozen in liquid nitrogen for lyophilisation (Thermo-Scientific) overnight. Due to the greater heterogeneity in tumour consistency, in order to clarify the supernatant from the fatty components of the tumour cell debris, the tumour samples were centrifuged and supernatant transferred to new eppendorf tubes twice prior to freezing in liquid nitrogen and lyophilisation. Samples were stored in -80°C.

Sample Preparation:
200 µl of a solution comprising of: 89.8% 2H2O, 10% (v/v) 1mM sodium phosphate (pH 7.4), 0.1% (v/v) 100 mM selectively deuterated (d4) trimethyl silyl propionate (TSP), and 0.1% (v/v) 1.2 mM sodium azide, was added per sample. Samples were vortexed for 1 minute followed by 2 minutes of centrifugation (20 °C, 12,000 g). The supernatant was pipetted into 3mm NMR tubes and arranged in an NMR tube rack. 

NMR Acquisition:
1D 1H NMR spectra were acquired on a Bruker Avance III HD 700MHz spectrometer equipped with a 5mm TCI cryoprobe at pH 7.4 and 25 °C. Two 1D 1H standard metabolomics experiments with optimal water suppression were acquired per sample; both are available in the Bruker pulse sequence library, the noesypr1d is based on the Nuclear Overhauser Effect (NOE) and the cpmgpr1d filters for small molecules via a Carr-Purcell-Meiboom-Gill (CPMG) sequence. The noesypr1d was acquired with 32 transients 20 ppm spectral width, 32K points, 10 ms mixing time and a 2.73 s acquisition time. The cpmgpr1d was acquired with 256 transients a 15 ppm spectral width, 32K points, 9.6 ms echo time and a 3.1 s acquisition time. Both spectra were acquired with a 4s interscan delay, the protein-free baseline of the cpmgpr1d resulted in these spectra used for downstream analysis.

Spectral Processing:
Automated data processing, Fourier transformation, and phasing were carried out in Topspin v3.2 software using standard Bruker routines. Chenomx v8.2 software was used for initial metabolite identification with manual confirmation to in-house standards for metabolite peaks found to be significantly variable. The spectra were then normalised to TSP reference signal and bucketed per peak into a matrix of metabolite peak intensities using AMIX v3.9.14. Statistical analysis was carried out using R (r-project.org) both standalone and via the metabolomics server Metaboanalyst v3.0 [34].

Statistical Analysis
The prepared bucket table was subjected to univariate and multivariate analysis. Student’s T-test were applied on the spectra after determining the data were parametric using ggplot function in R. Fold changes were calculated for median metabolite levels for buckets identified as significantly different by student t-test after p-value adjustment (Benjamini-Hochberg) to compensate for multiple testing. Unsupervised multivariate analysis of the spectra was carried after out using Principal Component Analysis (PCA). The data was scaled by mean centering of each variable followed by division of the square root of the standard deviation (Pareto scaling) before analysis. The PCA reduced the 300 spectral buckets of each sample to 15 principal components (PCs) in the combined analysis of tumours and cells (explaining 95% of the variance). The loadings of each PCA were analysed to identify the most influential buckets (and thus metabolites) responsible for the clustering observed. Following unsupervised analysis of the four conditions, cells and tumours were analysed separately by discriminant analysis of principal components (DAPC) and Partial Least Squares-Discriminant Analysis (PLS-DA). Both PLS-DA and DAPC models were fit using the optimal number of components as determined by cross validation using R packages ggplot and ade4. In order to elucidate the key metabolites in the separation of hypoxic and normoxic tumours or cells, a comparison of the most influential buckets for discriminant analysis was made both in the presence and absence of buckets attributed to unidentified metabolites. 

Results
Intratumoural oxygen levels are heterogeneous, fluctuating and only marginally altered by a cellular hypoxic preconditioning
Since we observed that SK-N-AS cell preconditioning in hypoxia for 3 days triggers a metastatic phenotype in tumours  ADDIN EN.CITE [8], we initially aimed to evaluate if the preconditioning could impact the actual tumour oxygenation. We performed precise live oxygen tension readings, with a fibre-optic sensor, in tumours formed on the CAM, from SK-N-AS cells pre-cultured in either atmospheric (21% O2) or hypoxic (1% O2) environment for three days. Measurements were done on >35 tumours in each condition over 14 batches of eggs (see colour coded experiments on Figure 1A, B) with readings being recorded at 2 second intervals for up to 57 min. Figure 1A, B shows a strong tumour to tumour variability, even within one experimental batch. The variation in tumour oxygenation was not correlated with tumour volume (supplementary Figure S2A). Nevertheless, the majority of all tumours, regardless of the preconditioning conditions, yielded a mean O2 tension less than 1% O2 (72.5%; n=58) and a quarter (26.3%; n=21) were in the range of 1-3% mean O2 tension (Figure 1C, table). The mean O2 tension was marginally higher in tumours originating from cells pre-cultured in normoxia compared to cells in hypoxia (mean O2 tension 0.98% ± 0.15 SEM versus 0.63% ± 0.08 SEM, with statistical significance (p=0.04; Figure 1C). Despite the significant p value, preconditioning the cells in a hypoxic environment did not have a major effect on the global tumour oxygenation (0.35% O2 difference), with tumours being globally hypoxic, similar to what was previously reported with oxygen measurements in various tumour types  ADDIN EN.CITE [35]. It has to be noted that several tumours had extremely low O2 levels, which were unusually very stable over time (see fluctuation box plot Figure 1D). These tumours have not been excluded from the statistics here, but likely come from measurements in blood pools or necrotic areas, which we have subsequently observed upon dissection and sectioning.
The range of O2 level fluctuation over time was measured with nine sets of measurements that were performed for more than 10 min (between 11 and 57 min) using a micromanipulator to increase measurement stability (Figure 1D). Fluctuations of oxygen tension were found to be similar in both conditions with 62.5% and 60.6% of tumours fluctuating less than 1% in tumours formed from normoxic and hypoxic precultured cells, respectively (Figure 1D, table). Cycle length and fluctuation range were found to be independent of the duration of the measurement (Supplementary Figure S2B) and of the hypoxic/normoxic preconditioning. Together, these data confirm that oxygen levels in neuroblastoma tumours are fluctuating moderately and that the metastatic phenotype, acquired by the hypoxic preconditioning results in a slightly lower overall mean of oxygen levels without influencing the occurrence of cycling hypoxia. The measurements were limited to a period of 57 min and it is possible that these tumours experience a slower cycling time, which could not be detected in this experimental set up. 

Metabolomic analysis of cell and tumour samples
To further establish the intracellular modifications triggered by hypoxic preconditioning, we analysed the metabolic signature of neuroblastoma cells and neuroblastoma tumours formed on the CAM by normoxic or hypoxic preconditioned cells. NMR spectroscopy was used to identify the metabolic shift induced by hypoxia. All data are available on EBI (http://www.ebi.ac.uk/metabolights/MTBLS541). A quantile plot of all 1D 1H NMR spectra is shown in supplemental Figure S3. The spectra were divided in 354 peaks or multiplets, of which 263 were assigned to a total of 98 metabolites. Data transformation using Principal Component Analysis (PCA) exhibited variance between the four groups of spectra with cells or tumours cultured under hypoxic conditions more varied than those under normoxic conditions (Figure 2A). As expected, the metabolic profile of cells cultured in vitro, was different and well separated from cells forming tumours on the CAM in vivo. Analysis of the loadings of metabolites that are most influential in the first and second principal components indicate that trehalose, glutathione, and mannose together with several unidentified metabolites contribute greatest to the variance between spectra (Figure 2B). The chemical shifts of the unknown components are consistent with saccharides (whose anomeric 1H shifts are observed between 4 and 6ppm) and/or molecules containing aromatic rings (shifts observed between 6 and 10 ppm).
Discriminant Analysis of Principal components (DAPC) was carried out to identify peaks and therefore metabolites responsible for spectral changes between the hypoxic and normoxic cell and tumour models (Figure 3). DAPC analysis required just one linear discriminant in order to distinguish between hypoxia and normoxia in either cells (Figure 3A) or tumours (Figure 3C). A comparison of the most influential metabolite signals (also referred to as buckets) responsible for the separation lead to the identification of metabolites that are at different abundances between normoxic and hypoxic conditions either in one or in both cell and tumour systems. Taurine, choline, lactate, myoinositol, n-acetylcysteine, and acetonitrile appear in both models. For example, the relative intensities for representative metabolite peaks for taurine are 17.89±4.3 in normoxic cells versus 21.61±2.24 in hypoxic cells, and 35.45±9.49 in normoxic tumours versus 23.07±5.27 in hypoxic tumours. Creatine, glutamate, uridine, n-acetyl-ornithine and aspartate appear in the 10% most influential buckets of the cellular DAPC model only (Figure 3B). Whereas tyrosine, 2-hydroxybutyrate, 3-hydroxybutyrate, ATP, malonate and glutathione appear in the most influential metabolite signals of the tumour DAPC model only (Figure 3D). Interestingly, DAPC analysis of the four conditions in one model exhibited greater differences between hypoxic and normoxic tumour profiles than between hypoxic and normoxic cell profiles (Supplementary Figure S4). With the two condition model presented in Figure 3, we identified taurine, choline, lactate, myoinositol, n-acetylcysteine and acetonitrile as being influential in normoxia-hypoxia group separation. 

Discriminant Analysis of specific metabolites to distinguish Hypoxia from Normoxia
In order to elucidate the key metabolites in the separation of hypoxic and normoxic tumours or cells, a comparison of the most influential buckets for discriminant analysis was made. From the DAPC loadings, twenty-two metabolites were identified for cells and twenty-one metabolites identified for tumours with only nine of the metabolites common to both systems. This shortlist of thirty four metabolite buckets is shown on the heatmap (Figure 4), with many exhibiting p values (adjusted for false discovery rate) consistent with significantly different metabolite levels between cells or tumour conditions. 
The shortlisted metabolites were then used exclusively to perform a Partial Least Squares Discriminant Analysis (PLS-DA) between hypoxic and normoxic conditions for either cells or tumours. The PLS-DA models for both cells and tumours were optimally fit with 5 components (cells) and 8 components (tumours) and yielded well defined separation between hypoxic and normoxic conditions with R2 and Q2 of 0.99 and 0.97, respectively, for the cellular model and 0.99 and 0.96, respectively, for the tumour model (Figure 5). Greater variation in the metabolite profile of tumour samples (as observed in Figure 2) may account for the slightly lower predictive Q2 score.

Contrasting metabolite fingerprints between neuroblastoma cells and tumours formed on the CAM: 
Most metabolite levels between hypoxic and normoxic conditions for the discriminating molecules exhibited differing trends between the cellular and tumour conditions (Figure 4 and 6). Of the thirty four metabolite buckets inspected, the majority (n=10) exhibited lower levels under hypoxic conditions including lactulose, sucrose, fructose, acetonitrile, glucose, DMSO, malonate, cystathione and citrate. It is likely that DMSO and acetonitrile are products of the culture media and extraction lysate, respectively. Multiple carbohydrates, citrate and ATP were also lower under hypoxic conditions, consistent with highly productive glycolysis and lower mitochondrial activity (citric acid cycle) in hypoxic conditions [36].
Five metabolites (3-hydroxybutyrate, lactate, GTP, taurine, and creatinine) were elevated in normoxic tumours compared to hypoxic tumours whereas, conversely, were elevated in hypoxic cells when compared to normoxic cells. In both cell and tumour extracts, four metabolites (isoleucine, 2-hydroxyvalerate, 2-hydroxybutyrate, and glutamate) were at significantly higher levels under hypoxic conditions (Figure 6 and supplementary Table 1). Unsurprisingly, the majority of metabolites are at higher levels in tumours than cells irrespective of oxygen levels with notable exceptions being media components glutamate, creatinine, and ATP. Myoinositol and choline were not significantly altered in either tumour or cell system however multivariate analysis has identified them as discriminant between hypoxic and normoxic conditions. This was evinced by the high VIP attributed to each in PLS-DA models, highlighting the importance of subtle distinctions not identified by crude univariate analysis.
Altogether, there are many differences between the cellular and tumour samples, with changes triggered by the hypoxic incubation occurring in opposite ways. The most notable one being the glycolytic pathway triggered, as expected, by the hypoxic incubation in cell culture (high levels of lactate), but not in tumours. However, this could be explained by the fact that the tumours show a much greater increase of the glycolytic pathway compared to the hypoxic cells (lactate and glucose). Nevertheless, despite many discrepancies between the in vitro and in vivo samples, some metabolite changes are consistent between the two, especially the lower levels of carbohydrates (fructose, sucrose, lactulose) in hypoxic cells and tumours in agreement with a productive glycolysis.

Discussion:
Neuroblastoma tumour formation on the CAM and its tuneable metastasis by hypoxic preconditioning, makes the chick embryo an ideal model to study the molecular mechanisms of hypoxia-induced metastasis. We have previously demonstrated that a 3 day hypoxic preconditioning of cells, prior to tumour formation elicits a clear metastatic phenotype, by triggering tumour cells intravasation, and by lowering their migration speed in blood vessels to facilitate extravasation  ADDIN EN.CITE [8]. We here show that these phenotypes are accompanied by some significant changes in the tumour cell metabolome, including high levels of ketones (3-hydroxybutyrate), lactate, and phospho-choline. Since the preconditioning does not strongly affect the global tumour oxygenation (0.35% O2 difference on average) nor the O2 fluctuation over time (Figure 1), the metabolomic signature observed in the tumours originating from hypoxic cells is likely due to the preconditioning rather than the actual tumour oxygen levels.

Tumour oxygenation: heterogeneity in space and time
Quantification of O2 levels in tumours has previously been reported to characterise the extent of tumour hypoxia in various malignancies, in both human patients and animal models  ADDIN EN.CITE [35, 37-45]. However, no oxygen tension data in neuroblastoma tumours are available. Our oxygen measurements and observed fluctuations correspond to others previously reported for glioblastoma and other brain tumours in humans with median values reported of 4.9mmHg (0.69% O2), 5.6mmHg (0.78 %O2), and 22.24mmHg (3.11%O2)  ADDIN EN.CITE [6, 45, 46]. We aimed to detect and quantify the cycling pattern and fluctuation in O2 levels, which were previously reported in mice models by Dewhirst and others  ADDIN EN.CITE [3, 47, 48]. Although we did not identify clear cycles of hypoxia-reoxygenation (Supplementary Figure S5), we clearly observed variations over time within a 1% range in O2 levels in most of the cases (Figure 1D, E). These observations are in line with others, which found that 8-20% of tumour cells experience oxygen fluctuation when measured with hypoxic markers [47]. Our higher number of fluctuating tumours is likely due to the fact that we performed direct O2 measurements, instead of relying on less sensitive hypoxic markers as in [36]. The variations observed are also comparable to the previously observed phenomenon of intermittent, or cycling, hypoxia in human and animal tumour models  ADDIN EN.CITE [3, 49, 50].

Metabolic signature of hypoxia in cells and tumours
Previous studies have compared the metabolomic fingerprint of cells cultured in normoxia and hypoxia at different time points  ADDIN EN.CITE [51, 52]. In both cases, measurements were performed at both short (4h or 6h) and long (48h) hypoxic incubation. It is difficult, however, to find a strong consensus between the different cell lines. The increased level of lactate and lower levels of myo-inositol from Tsai et al [52] is comparable to our observations. However, our results show that these changes detected in cells are different in the tumour samples. The several discrepancies that we observed between cells and in vivo tumours point to the necessity to carefully choose the cancer model and question the usefulness of the in vitro data. Comparisons between in vitro and in vivo metabolic profiles of cells subjected to hypoxia demonstrate the remarkable differences in metabolic alterations by the hypoxic pre-conditioning in the two different situations. One major difference, which might account for the varying results between cell samples and tumours, beyond the different microenvironment, is that with cell samples, only the intracellular metabolites were measured, with extracellular component washed away with the media. In tumour samples, however, there will be a mix of tumour cells, stromal cells, and although tissue is washed it is likely to contain residual secreted metabolites. 
The higher levels of taurine found in hypoxic cells compared to normoxic ones is in line with observations in glioblastoma cell lines [51] and might be an adaptation mechanism for cells to survive better in hypoxic conditions. Indeed, it has been shown that taurine can protect human neuroblastoma cells in culture  ADDIN EN.CITE [53] and may exert a protective function against hypoxia/reoxygenation by reducing the ER stress  ADDIN EN.CITE [54]. In addition, taurine administered during hypoxia can reduce the cell damage due to O2 deficiency [55]. High taurine levels were also found in MYC-N amplified neuroblastoma cells lines in a study by Peet et al, again pointing to a link between taurine levels and tumour aggressive phenotype [56]. However, in vivo, taurine levels were decreased in tumours formed by hypoxic cells, which are the most metastatic ones, hence discrediting the in vitro findings. Nonetheless, this is consistent, with the EMT inhibitory effect of taurine in human prostate cancer cells [57], and suggest that the decreased levels, would be favourable to the metastatic process.
We found that the non-essential amino-acid glutamate was consistently higher in hypoxic cells and in tumours from hypoxia-preconditioned cells. This is consistent with the role of glutamate, beyond being an excitatory neurotransmitter, in the regulation of proliferation, migration, and survival of normal neuronal progenitor cells  ADDIN EN.CITE [58, 59] and neoplastic cells [60]. 

The tumour metabolome
Some metabolite levels in the tumour samples correlated well with existing literature on tumour metabolomics. The low levels of creatine and myo-inositol and high levels of lactate and choline in the tumour samples are in line with the level of expression of these metabolites in tumour tissues, shown by a recent meta-analysis of the metabolic profile of 18 tumour types  ADDIN EN.CITE [23]. However, the lower-levels of acetate and creatine in hypoxic metastatic tumours is surprising as high levels of acetate and creatine were found in stage IV human neuroblastoma biopsy samples [25]. Interestingly, hypoxic cells seemed to share more elevated metabolite levels observed in human neuroblastoma tissue [25] than the CAM tumours. The end-products of aerobic glycolysis: 3-hydroxy-butyrate and lactate both have the same profile of regulation. They are at higher levels in hypoxic cells, consistent with the high glycolytic activity induced by the hypoxic environment, and they are observed at much higher levels in tumours compared to cells. Yet, they are not further elevated in the tumours formed by hypoxic-preconditioned cells compared to tumours from normoxic cells, potentially due to the very high levels already reached in tumours. Administration of 3-hydroxy-butyrate increased tumour growth by ∼2.5-fold in a model of MDA-MB-231 breast cancer xenografts  ADDIN EN.CITE [61]. In this model, both 3-hydroxy-butyrate and L-lactate functioned as chemo-attractants and stimulated the migration of epithelial cancer cells while lactate stimulated the formation of lung metastases. Therefore, the high levels of ketones and lactate found in our tumour model is consistent with their previously reported role in fuelling tumour growth and metastasis  ADDIN EN.CITE [61].
In conclusion, we have demonstrated that neuroblastoma tumours formed on the CAM of the chick embryo have a heterogeneous profile of oxygenation in time and space, but are mostly hypoxic (<1.5% O2) as previously reported in other human tumour types. We identified a very specific metabolite profile in cells and in tumours and could discriminate well the effects of hypoxic incubation in vitro or hypoxic preconditioning in vivo. Whilst the most notable effect of hypoxia in vitro was the expected increased levels of the metabolites associated with glycolysis; in vivo, the effects ranged from a decrease of carbohydrates, ATP and taurine and an increase of ADP, isoleucine and glutamate, and their direct association with neuroblastoma metastasis will need to be further investigated.
Figure Legends:
Figure 1: Mean Oxygen Tension Measurements. Intratumoural O2 tension readings were measured up to 57 minutes, using a fibre-optic oxygen measurement probe. The O2 levels plotted are the mean levels measured during the recording. A. Mean oxygen tension of 38 tumours from normoxic cells, colour coded by experiment to allow sample matching with B. B. Mean oxygen tension of 42 hypoxic tumours. Measurements were performed over 14 batches of eggs. In 2 replicates, measurements were only obtained from one condition and could not be matched (light blue and purple). C. The bar graph displays the overall mean oxygen tension ± S.E.M of the normoxic and hypoxic tumours calculated as a mean of mean measurements in each sample type. p < 0.05. The table shows the distribution of tumours in indicated oxygenation categories. Note that a few tumours had very low O2 levels, with no fluctuations and were taken in tumours which showed to have large blood pools or necrotic areas upon sectioning. D. Oxygenation fluctuation was measured on a subset of tumours, using a micromanipulator to avoid measurement errors over time. The boxplots display the range of oxygen tension in tumours during the measurement period (from 11 to 57 min). Each plot represents a single tumour. The table displays the % of tumours in different fluctuation ranges (from non-fluctuating: <0.2% O2 difference over time, to high fluctuating: >3% O2 difference over time) for tumours originating from normoxic or hypoxic preconditioned SK-N-AS cells. 

Figure 2: PCA of cell and tumour metabolite extracts. A. Scores plot shows greater variance in spectra of hypoxic samples (cells in black and tumours in blue) compared to samples cultured under normoxic conditions (cells in red and tumours in green). B. Most influential buckets from PC1 and PC2 (combined). Numbers reported in parenthesis adjacent to variables represent the centre of the metabolite peak in ppm +/- 0.005.

Figure 3: DAPC plots of total NMR metabolite profiles from cells (A, B) and tumours (C, D) under hypoxic and normoxic conditions. Linear discriminant 1 for A) hypoxic and normoxic cells shown in black and red respectively and C) hypoxic and normoxic tumours shown in blue and green respectively. Most influential buckets for the DAPC models for cells B) and tumours D). Numbers reported in parenthesis adjacent to variables represent the centre of the metabolite peak in ppm +/- 0.005.

Figure 4: Fold-Change heatmap for thirty-three shortlisted metabolite peaks that are used to distinguish normoxic from hypoxic conditions in either cells or tumours. Heatmap colour only shown where metabolite levels are deemed significantly different below a p-value 0.05 (p values adjusted for multiple testing by Benjamini-Hochberg method).

Figure 5: PLS-DA models using shortlist of metabolites for either cells (A, B) or tumours (C, D) under hypoxic (red or green) and normoxic (black or blue) conditions. Variable Influencing permutation (VIP) scores (B and D) rank the influence of the metabolites over the model (for all components).

Figure 6: Boxplots of representative metabolite peaks listed in Figure 4 for normoxic SK-N-AS Cells (CN), hypoxic SK-N-AS cells (CH), tumours from normoxic cells (TN) and tumours from hypoxic cells (TH). Bars represent significantly difference between groups (Tukeys post-hoc analysis, adjusted p-value <0.05). The relative intensity and standard deviation for representative metabolite peaks are also provided as numbers in supplementary Table 1.
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Supplementary Material:
Supplementary Figure S1: Cell proliferation, death and confluence for NMR measurement. A. Number of viable cells cultured under normoxic (blue) or hypoxic (red) conditions. 1x106 SK-N-AS cells were seeded on day 0 and incubated either in normoxia or hypoxia. On days 1, 2 and 3, cells were harvested as described in the Materials and Methods Section, stained with 0.4% Trypan Blue Solution (Biorad) and counted with a cell counter (TC20TM, Biorad). Viable cells were plotted as a function of culture duration. B. Cells were cultured and harvested as described in A, and dead (Trypan blue positive cells) were plotted as a function of culture duration. C. Representative bright-field image of SK-N-AS cells 3 d after culture in normoxia or hypoxia showing confluency on the harvest day for NMR samples. 

Supplementary Figure S2: Oxygen levels as a function of tumour volume and oxygen fluctuation over time. A. The tumour volume for all tumours (formed by normoxic and hypoxic preconditioned cells) was measured (as previously described by Herrmann et al.  ADDIN EN.CITE [8]). O2 levels were plotted as a function of the tumour volume. There was no correlation between tumour volume and intra-tumoural oxygen levels in either condition. B. Red and blue bars represent the mean fluctuation ranges of normoxic and hypoxic tumours, respectively. Error bars indicate the standard deviation. There is no notable difference in fluctuation over time with a 0.1% increase in range in the longer measurements within the same condition. Overall fluctuation of all the normoxic and hypoxic tumours are 0.95% and 1.0% ranges, respectively.

Supplementary Figure S3: Quantile plots of all cell and tumour extract spectra. The median spectral plot is represented by a black line and the quantiles (variation from the median) shown from yellow to red within each group. The full spectrum comprises all 72 sample spectra with the insets shown per group with 28 spectra comprising extracts ('Cells') and 44 spectra comprising tumour extracts ('Tumours').

Supplementary Figure S4: DAPC plots of total NMR metabolite profiles from both cells and tumours under hypoxic and normoxic conditions. A. Scores plot for Linear discriminant 1 and 2 for hypoxic cells (black), normoxic cells (red), hypoxic tumours (blue) and normoxic tumours (green). B. Most influential buckets for the DAPC model LD1and LD2 combined.

Supplementary Figure S5: Time-lapse measurements of 3 typical oxygen readings recorded by a fibre-optic oxygen microsensor in 3 neuroblastoma tumours on the CAM of chick embryos.

Supplementary Table 1: Median relative intensity and standard deviation for representative metabolite peaks shortlisted for discriminant analysis
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